The new acting FDA commissioner, Kyle Diamantas, intends to increase the use of Advisory Committee meetings (AdComs). This is a significant procedural shift that suggests a move away from the previous leadership's more top-down, centralized decision-making. It signals a greater reliance on external experts and career staff, potentially leading to more transparent and predictable regulatory outcomes.

The FDA is creating a transparency paradox. It is increasingly publishing complete response letters (CRLs), giving insight into why drugs are rejected. Simultaneously, it has drastically cut the number of public advisory committee (AdCom) meetings held before approval decisions, reducing public input and pre-decision transparency.

Disagreements between FDA review teams and senior leadership, like CBER head Vinay Prasad, create contradictory guidance for drug sponsors. Companies follow the review team's advice, only to be overruled by leadership, leading to wasted resources, delayed approvals, and significant frustration.

The current intense scrutiny of the FDA is not just about controversial decisions, but a belief that political influence is overriding scientific judgment. This perception erodes the public trust and credibility the agency needs to make tough, science-based calls, turning every decision into a political battle.

Reporting reveals that FDA staff are fearful of Director Prasad due to his tendency to overturn scientific decisions and push out senior leaders. This environment stifles the voices of career scientists and has led to a "deleterious effect" on the center, potentially compromising the integrity of the review process.

Internal power shifts at the FDA, such as Vinay Prasad's rising influence, create a chilling effect on review teams. Even without direct orders, reviewers feel less emboldened to be flexible when leadership's public stance favors greater rigor. This 'tone from leadership' can shift regulatory outcomes more than explicit policy changes.

The HHS Secretary's unprecedented interview of a candidate for FDA's CEDAR Director marks a significant politicization of a traditionally scientific, civil service position. This shift suggests future directors may need political alignment with the administration, leading to greater risk aversion, erratic decision-making, and less predictability for the biopharma industry.

The current disconnect between the FDA leadership's public calls for flexibility and its divisions' strict actions is not new. For decades, the agency's hierarchy has acted as a promotional arm to encourage industry, while the review divisions have maintained a more conservative, old-school approach to rigor. This historical pattern is often overlooked.

Recent leadership changes at the FDA, driven by politics, have replaced experienced staff with more conservative, 'safe' appointments. This is expected to lead to more rigid regulatory decisions and a period of instability, impacting biopharma companies seeking approvals.